200 related articles for article (PubMed ID: 30073889)
1. Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Liang YY; Zhang CM; Liu ZP
Expert Opin Ther Pat; 2018 Aug; 28(8):647-651. PubMed ID: 30073889
[TBL] [Abstract][Full Text] [Related]
2. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
4. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Shen S; Kozikowski AP
Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
[No Abstract] [Full Text] [Related]
5. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
Ptacek J; Snajdr I; Schimer J; Kutil Z; Mikesova J; Baranova P; Havlinova B; Tueckmantel W; Majer P; Kozikowski A; Barinka C
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902164
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
9. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
[TBL] [Abstract][Full Text] [Related]
11. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
Cellupica E; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Rocchio I; Sandrone G; Vanoni MA; Vergani B; Źrubek K; Stevenazzi A; Steinkühler C
J Biol Chem; 2023 Jan; 299(1):102800. PubMed ID: 36528061
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
[TBL] [Abstract][Full Text] [Related]
13. Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase
König B; Watson PR; Reßing N; Cragin AD; Schäker-Hübner L; Christianson DW; Hansen FK
J Med Chem; 2023 Oct; 66(19):13821-13837. PubMed ID: 37782298
[TBL] [Abstract][Full Text] [Related]
14. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
15. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
16. Development of the first non-hydroxamate selective HDAC6 degraders.
Keuler T; König B; Bückreiß N; Kraft FB; König P; Schäker-Hübner L; Steinebach C; Bendas G; Gütschow M; Hansen FK
Chem Commun (Camb); 2022 Oct; 58(79):11087-11090. PubMed ID: 36098075
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
18. Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
Ripa L; Sandmark J; Hughes G; Shamovsky I; Gunnarsson A; Johansson J; Llinas A; Collins M; Jung B; Novén A; Pemberton N; Mogemark M; Xiong Y; Li Q; Tångefjord S; Ek M; Åstrand A
J Med Chem; 2023 Oct; 66(20):14188-14207. PubMed ID: 37797307
[TBL] [Abstract][Full Text] [Related]
19. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
